© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
Related Content:
News